Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time"
Before the turn of the year, Eli Lilly will receive the phase III results for the drug tirzepatide, meant to beat the best products in the top-selling GLP-1 segment on the diabetes market. Jamie Croaning, who leads the development of the drug at Eli Lilly, speaks of a paradigm shift.
BY KEVIN GRØNNNEMANN, TRANSLATED BY NIELSINE NIELSEN
Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Astrazeneca's covid antibody drug heads into advanced trials
For subscribers
Lundbeck plans to succeed with migraine drug – Teva failed
For subscribers
